ABOS - Acumen Pharmaceuticals, Inc.
2.26
-0.290 -12.832%
Share volume: 919,327
Last Updated: 03-27-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$2.55
-0.29
-0.11%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2024 | 08-13-2024 | 11-12-2024 | 03-27-2025 | 05-13-2025 | 11-12-2025 | 03-26-2026 | |
| Assets | ||||||||
| Total Assets | 300.967 M | 288.913 M | 266.975 M | 238.992 M | 204.478 M | 142.221 M | 122.833 M | |
| Current Assets | 255.831 M | 266.915 M | 207.632 M | 178.306 M | 154.947 M | 132.153 M | 122.252 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 205.582 M | 192.517 M | 167.159 M | 135.930 M | 118.989 M | 79.777 M | 62.876 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 46.930 M | 67.955 M | 33.184 M | 35.627 M | 30.159 M | 46.832 M | 53.989 M | |
| Total Non-current Assets | 44.108 M | 20.908 M | 58.552 M | 59.968 M | 48.795 M | 9.443 M | 0.000 | |
| Property Plant Equipment | 117.000 K | 105.000 K | 89.000 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 45.019 M | 21.893 M | 59.254 M | 60.454 M | 49.531 M | 10.068 M | 581.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 300.967 M | 288.913 M | 266.975 M | 238.992 M | 204.478 M | 142.221 M | 122.833 M | |
| Total liabilities | 38.933 M | 44.966 M | 49.773 M | 57.176 M | 48.957 M | 49.048 M | 52.403 M | |
| Total current liabilities | 8.472 M | 15.367 M | 19.914 M | 27.607 M | 19.315 M | 21.956 M | 30.007 M | |
| Accounts Payable | 3.079 M | 4.211 M | 2.342 M | 5.648 M | 1.056 M | 682.000 K | 554.000 K | |
| Other liabilities | 252.000 K | 219.000 K | 185.000 K | 150.000 K | 114.000 K | 39.000 K | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 30.209 M | 29.380 M | 29.674 M | 29.419 M | 29.528 M | 27.053 M | 22.396 M | |
| Other liabilities | 252.000 K | 219.000 K | 185.000 K | 150.000 K | 114.000 K | 39.000 K | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 262.034 M | 243.947 M | 217.202 M | 181.816 M | 155.521 M | 93.173 M | 70.430 M | |
| Common stock | 499.849 M | 502.319 M | 504.657 M | 506.991 M | 509.429 M | 514.388 M | 516.809 M | |
| Retained earnings | -237.671 M | -258.208 M | -287.973 M | -325.127 M | -353.923 M | -421.324 M | -446.462 M |